Exelixis (EXEL) Receives a Hold from RBC Capital

RBC Capital analyst Leonid Timashev maintained a Hold rating on Exelixis yesterday and set a price target of $45.00. The company’s shares closed yesterday at $41.07.

Claim 50% Off TipRanks Premium and Invest with Confidence

• Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential

According to TipRanks, Timashev is a 5-star analyst with an average return of 30.9% and a 57.92% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Alkermes, Exelixis, and Legend Biotech.

In addition to RBC Capital, Exelixis also received a Hold from Barclays’s Etzer Darout in a report issued today. However, on December 9, TR | OpenAI – 4o reiterated a Buy rating on Exelixis (NASDAQ: EXEL).

Based on Exelixis’ latest earnings release for the quarter ending October 3, the company reported a quarterly revenue of $597.76 million and a net profit of $193.58 million. In comparison, last year the company earned a revenue of $539.54 million and had a net profit of $117.97 million

Based on the recent corporate insider activity of 90 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EXEL in relation to earlier this year. Last month, DAVID EDWARD JOHNSON, a Director at EXEL bought 27,532.00 shares for a total of $1,187,179.84.